While, on the one hand, the development of drugs designed to block UBE2O activity could provide a relevant mechanism for the inhibition of the progression of many tumors and for an improvement in insulin sensitivity and systemic physiology, on the other hand, UBE2O is required for erythropoiesis and has showed a favorable role in some hematological diseases. This evidence concerns the gene UBE2O and hematologic disorder.